Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RIST4271
- Development stage
- Discontinued
- Lead developer
- Aristea Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RIST4271 is a small molecule, oral C-X-C motif chemokine receptor 2 (CXCR2) antagonist. It was developed by Aristea Therapeutics, an AstraZeneca spin-out, for the treatment of serious inflammatory diseases. CXCR2 plays a crucial role in recruiting neutrophils to inflammatory sites, and by blocking this receptor, RIST4271 aimed to reduce inflammation. The development program for RIST4271 was discontinued in February 2023 due to safety findings in ongoing Phase 2 clinical trials, leading to the dissolution of Aristea Therapeutics.
- Other names
- RIST-4721RIST4721RIST 4721AZD-4721AZD4721AZD 4721
02
Targets
CXCR2 (C-X-C Motif Chemokine Receptor 2)
Beyond the preview
Go deeper on RIST4271.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RIST4271.